Fortrea Holdings (FTRE) Capital Expenditures (2022 - 2026)
Fortrea Holdings (FTRE) posted Capital Expenditures of $8.0 million for Q1 2026, up 6.67% on a QoQ basis from $7.5 million in Q4 2025, and up 175.86% year-over-year from $2.9 million in Q1 2025.
Fortrea Holdings (FTRE) Capital Expenditures (2022 - 2026) Analysis & Trends
Fortrea Holdings' Capital Expenditures history runs 5 years deep, the most recent figure standing at $8.0 million for Q1 2026.
- Quarterly Capital Expenditures rose 175.86% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.3 million (up 58.64% YoY) and the FY2025 annual result came in at $25.2 million, down 1.18% from the prior year.
- Capital Expenditures was $8.0 million for Q1 2026 at Fortrea Holdings, up from $7.5 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $18.4 million in Q4 2022 and bottomed at -$3.2 million in Q4 2024.
- A 5-year average of $9.0 million and a median of $8.2 million in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2024 — Capital Expenditures slumped 134.04% — and 2025, when it jumped 334.38%.
- Fortrea Holdings' Capital Expenditures stood at $18.4 million in 2022, then sank by 48.91% to $9.4 million in 2023, then slumped by 134.04% to -$3.2 million in 2024, then soared by 334.38% to $7.5 million in 2025, then grew by 6.67% to $8.0 million in 2026.
- Business Quant data shows FTRE's Capital Expenditures at $8.0 million in Q1 2026, $7.5 million in Q4 2025, and $7.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.00 Mn |
| Mar 31, 2026 | 8.00 Mn |
| Dec 31, 2025 | 7.50 Mn |
| Dec 31, 2025 | 7.50 Mn |
| Sep 30, 2025 | 7.30 Mn |
| Sep 30, 2025 | 7.30 Mn |
| Jun 30, 2025 | 7.50 Mn |
| Jun 30, 2025 | 7.50 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | -3.20 Mn |
| Dec 31, 2024 | -3.20 Mn |
| Sep 30, 2024 | 8.20 Mn |
| Sep 30, 2024 | 8.20 Mn |
| Jun 30, 2024 | 11.20 Mn |
| Jun 30, 2024 | 11.20 Mn |
| Mar 31, 2024 | 9.30 Mn |
| Mar 31, 2024 | 9.30 Mn |
| Dec 31, 2023 | 9.40 Mn |
| Dec 31, 2023 | 9.40 Mn |